RGEN Quote, Financials, Valuation and Earnings

QuidelOrtho has a net margin of -0.42% compared to Repligen's net margin of -2.74%. Repligen's return on equity of -0.41% beat QuidelOrtho's return on equity of -47.52%.

Repligen has a consensus price target of $191.46, signalling upside risk potential of 30.29%. On the other hand QuidelOrtho has an analysts' consensus of -- which suggests that it could grow by 14.72%. Given that Repligen has higher upside potential than QuidelOrtho, analysts believe Repligen is more attractive than QuidelOrtho.

Repligen has a beta of 0.965, which suggesting that the stock is 3.502% less volatile than S&P 500. In comparison QuidelOrtho has a beta of 0.107, suggesting its less volatile than the S&P 500 by 89.318%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. QuidelOrtho offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. QuidelOrtho pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $154.9M, which are smaller than QuidelOrtho quarterly revenues of $727.1M. Repligen's net income of -$654K is higher than QuidelOrtho's net income of -$19.9M. Notably, Repligen's price-to-earnings ratio is 628.56x while QuidelOrtho's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 13.04x versus 1.06x for QuidelOrtho. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -0.42% compared to Repligen's net margin of -4291.67%. Repligen's return on equity of -0.41% beat Catheter Precision's return on equity of -65.84%.

Repligen has a consensus price target of $191.46, signalling upside risk potential of 30.29%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 429.24%. Given that Catheter Precision has higher upside potential than Repligen, analysts believe Catheter Precision is more attractive than Repligen.

Repligen has a beta of 0.965, which suggesting that the stock is 3.502% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $154.9M, which are larger than Catheter Precision quarterly revenues of $96K. Repligen's net income of -$654K is higher than Catheter Precision's net income of -$4.1M. Notably, Repligen's price-to-earnings ratio is 628.56x while Catheter Precision's PE ratio is 0.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 13.04x versus 1.01x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of -0.42% compared to Repligen's net margin of 18.21%. Repligen's return on equity of -0.41% beat West Pharmaceutical Services's return on equity of 18.16%.

Repligen has a consensus price target of $191.46, signalling upside risk potential of 30.29%. On the other hand West Pharmaceutical Services has an analysts' consensus of $378.17 which suggests that it could grow by 13.64%. Given that Repligen has higher upside potential than West Pharmaceutical Services, analysts believe Repligen is more attractive than West Pharmaceutical Services.

Repligen has a beta of 0.965, which suggesting that the stock is 3.502% less volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.007, suggesting its more volatile than the S&P 500 by 0.671%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services offers a yield of 0.24% to investors and pays a quarterly dividend of $0.21 per share. Repligen pays -- of its earnings as a dividend. West Pharmaceutical Services pays out 9.61% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Repligen quarterly revenues are $154.9M, which are smaller than West Pharmaceutical Services quarterly revenues of $746.9M. Repligen's net income of -$654K is lower than West Pharmaceutical Services's net income of $136M. Notably, Repligen's price-to-earnings ratio is 628.56x while West Pharmaceutical Services's PE ratio is 49.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 13.04x versus 8.56x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -0.42% compared to Repligen's net margin of -17.98%. Repligen's return on equity of -0.41% beat Xtant Medical Holdings's return on equity of -35.98%.

Repligen has a consensus price target of $191.46, signalling upside risk potential of 30.29%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 469.04%. Given that Xtant Medical Holdings has higher upside potential than Repligen, analysts believe Xtant Medical Holdings is more attractive than Repligen.

Repligen has a beta of 0.965, which suggesting that the stock is 3.502% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $154.9M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. Repligen's net income of -$654K is higher than Xtant Medical Holdings's net income of -$5M. Notably, Repligen's price-to-earnings ratio is 628.56x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 13.04x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.